<DOC>
	<DOCNO>NCT00097903</DOCNO>
	<brief_summary>The purpose study determine maximum safe dose orally administer Karenitecin ( BNP1350 ) patient solid tumor .</brief_summary>
	<brief_title>Trial Oral Karenitecin Patients With Solid Tumors Lung Cancer</brief_title>
	<detailed_description>Initially , safety , side effect recommend phase 2 dose oral Karenitecin patient advance solid tumor determine . When recommend phase 2 dose determine , specify dose use determine Karenitecin effective treatment patient relapse refractory non-small cell lung cancer .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion Criteria Patients enter Phase 1 portion study must histologically cytologically documented diagnosis cancer ( solid tumor ) refractory conventional therapeutic modality conventional treatment exists . Patients enter Phase 2 portion study must histologically cytologically document diagnosis advance ( Stage IIIb/IV ) NSCLC . Patients enter Phase 1 portion study either measurable evaluable disease . Patients enter Phase 2 portion study must measurable disease meeting RECIST criterion . Patients must ECOG performance status less equal 1 . More 2 week must elapse since previous chemotherapy 6 week previous treatment nitrosoureas mitomycinC . Patients must fully recover toxic effect prior therapy . Patients enter Phase 1 portion study may receive two prior chemotherapy program include adjuvant neoadjuvant therapy . Patients enter Phase 2 portion study may receive one prior chemotherapy program include adjuvant neoadjuvant therapy NSCLC . More 2 week must elapse since previous radiation therapy prior radiation must less equal 15 % bone marrow . Required Initial Laboratory Data : *ANC ≥ 1,500/mm3 , *Platelet count ≥ 100,000/mm3 , *SGPT &lt; 1.5 time ULN , *Alkaline phosphatase &lt; 2.0 time ULN , *Bilirubin &lt; 1.5 mg/dl , *Serum creatinine &lt; 1.5 time ULN Pregnant lactate woman . Uncontrolled high blood pressure , uncontrolled diabetes mellitus , unstable angina , symptomatic congestive heart failure ( CHF ) , myocardial infarction ( MI ) within 6 month , uncontrolled arrhythmia . Phase 2 previous concurrent malignancy Central Nervous System ( CNS ) metastasis neurologically unstable require steroid use . Active infection . Known positive HIV status . Conditions require use H2 blocker antacid . Inability provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Oral</keyword>
</DOC>